Health
Trump Drops Biden’s Medicare Obesity Drug Coverage Proposal
This article is for subscribers only.
The Trump administration decided against allowing Medicare to pay for obesity drugs, a move that would have given millions of older Americans access to the medications and cost the government billions.
The highly anticipated decision sent shares of obesity drugmakers Eli Lilly & Co. and Novo Nordisk A/S lower.